Darzalex (daratumumab) could be a antibody that blocks a definite macromolecule within the body that may have an effect on growth cell growth. Organism antibodies ar created to focus on and destroy solely bound cells within the body. This could facilitate to safeguard healthy cells from injury.
Darzalex is employed to treat myeloma (bone marrow cancer). Darzalex is typically given once alternative cancer medicines are tried while not success.

Darzalex was approved by the U.S. Food and Drug Administration (FDA) on an “accelerated” basis. In clinical studies, patients with myeloma skillful this medication. However, additional studies ar required.

Submit your review
1
2
3
4
5
Submit
     
Cancel

Create your own review

Average rating:  
 0 reviews
  • Darzalex
  • Get emergency medical help if you have signs of an allergic reaction to Darzalex: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

    Some side effects may occur during the injection. Tell your caregiver right away if you feel dizzy, itchy, cold, nauseated, or if you have a headache, stuffy nose, runny nose, trouble breathing, or a tight feeling in your throat.

    Call your doctor at once if you have:

    fever, chills, cough with yellow or green mucus;
    stabbing chest pain, wheezing, feeling short of breath;
    numbness, tingling, or burning pain;
    a red or blistering skin rash; or
    low blood cell counts - fever, chills, flu-like symptoms, swollen gums, mouth sores, skin sores, rapid heart rate, pale skin, easy bruising, unusual bleeding, feeling light-headed.
    Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

    Common Darzalex side effects may include:

    nausea;
    feeling tired;
    back pain; or
    cold symptoms such as stuffy nose, sneezing, cough, sore throat.
  • Recommended dose: 16 mg/kg IV once a week on weeks 1 thru 8, then 16 mg/kg IV every 2 weeks on weeks 9 thru 24, then 16 mg/kg IV every 4 weeks from week 25 onwards until disease progression Manufacturer recommended infusion rates: FIRST INFUSION: -Dilution volume: 1000 mL -Initial rate (first hour): 50 mL/hr -Rate increment: 50 mL/hr every hour -Maximum rate: 200 mL/hr SECOND INFUSION: -Dilution volume: 500 mL -Initial rate (first hour): 50 mL/hr -Rate increment: 50 mL/hr every hour -Maximum rate: 200 mL/hr -COMMENT: Escalate only if there is no Grade 1 (mild) or greater infusion reactions during the first 3 hours of the first infusion. SUBSEQUENT INFUSIONS: -Dilution volume: 500 mL -Initial rate (first hour): 100 mL/hr -Rate increment: 50 mL/hr every hour -Maximum rate: 200 mL/hr -COMMENT: Escalate only if there is no Grade 1 (mild) or greater infusion reactions during a final infusion rate of 100 mL/hr or greater in the first 2 infusions.